- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Central precocious puberty (CPP)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1212KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 80KB)
Triptorelin – July 2021
Triptorelin: Powder for I.M. injection (prolonged release) 22.5 mg (as embonate), with solvent; Diphereline®
Last updated
29 October 2021